Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

Lisa A. Carey, MD, on Triple-Negative Breast Cancer: Clinical Implications of Findings on Paclitaxel and Atezolizumab

Posted: Sunday, October 4, 2020

Lisa A. Carey, MD, of the University of North Carolina, compares the negative findings of IMpassion131 with other similar studies in a discussion of prescribing paclitaxel and atezolizumab for patients with locally advanced or metastatic triple-negative breast cancer.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.